// App-Quantinova.ai

108 : Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.

Researchers

Presenter

  • Benjamin Adam Weinberg

Principal Investigators

  • Manel Rakez

  • Benoist Chibaudel

  • Tim Maughan

  • Richard Adams

  • John Raymond Zalcberg

  • Axel Grothey

  • Takayuki Yoshino

  • Qian Shi

  • Aimery De Gramont

  • Dustin A. Deming

Medical Centers

  • Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Statistical Unit, ARCAD Foundation, Levallois-Perret, France

  • Franco-British Institute, Levallois-Perret, France

  • CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, United Kingdom

  • Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • West Cancer Center, OneOncology, Germantown, TN

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, Japan

  • Mayo Clinic, Rochester, MN

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

Locations

  • United States

  • France

  • United Kingdom

  • Australia

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved